Pryor Cashman Represents Lead Investor Soleus Capital in BioAtla's $72.5 Million Series D Financing
Pryor Cashman represented Soleus Capital as the lead investor in a notable $72.5 million Series D financing of BioAtla, Inc., alongside a prominent roster of leading investment funds from the life sciences sector, including HBM Healthcare Investments as co-lead, Cormorant Asset Management, Farallon Capital, Pappas Capital, funds managed by Janus Henderson, Boxer Capital, and an unnamed institutional investor. Current investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), also participated in the financing, which closed on July 13, 2020.
The press release announcing the deal can be found here.
The Pryor Cashman team was led by partner Michael Weinsier, co-head of the firm's Private Equity practice, with principal assistance from Corporate associate Royce Liu. Partner Jeffrey Snow and associate Joseph Micali, from the firm's Intellectual Property Group, and partner Michael Dunworth and associate Taylor Weinstein from the firm's Tax Group, also assisted in the transaction.
About Soleus Capital
Soleus Capital Management, L.P. is a healthcare investment firm focused on the innovative areas of life sciences, including biotechnology, and medical technology. Soleus Capital's interest spans across the healthcare lifecycle from developmental-stage companies through commercial companies.
